Ming-Ming Zhou, Ph.D., is a scientist who focuses on structural and chemical biology, NMR spectroscopy and drug design. He is currently the Dr. Harold and Golden Lamport Professor and Chairman of the Department of Pharmacological Sciences and Co-Director of the Drug Discovery Institute at the Icahn School of Medicine at Mount Sinai and Mount Sinai Health System in New York City as well as Professor of Sciences. Mr.Zhou has published more than 180 research articles and is an inventor of 28 patents. His research has been funded by grants from federal, state and private research foundations including the National Institutes of Health, the National Science Foundation, the New York State Stem Cell Science, the Institute for the Study of Aging, the American Foundation for AIDS Research, the American Cancer Society, GlaxoSmithKline, the Michael J. Fox Foundation, the Samuel Waxman Cancer Research Foundation, and the Wellcome Trust. He serves on the board of directors at the New York Structural Biology Center, as well as on the editorial boards of ACS Medicinal Chemistry Letters, the Journal of Molecular Cell Biology and Cancer Research. Zhou received the GlaxoSmithKline Drug Discovery Research Award in 2003 for his work in anti-HIV/AIDS therapy development, and the Jacobi Medallion in 2019. He is an elected fellow of the American Association for the Advancement of Science (2012). Biography Zhou earned his B.E. in chemical engineering from the East China University of Science and Technology (Shanghai, PRC) in 1984. He earned his M.S. in chemistry from the Michigan Technological University in 1988 and a Ph.D. in chemistry from Purdue University in Indiana in 1993. He completed his postdoctoral fellowship at Abbott Laboratories in Chicago, Illinois, then joined the faculty of the Mount Sinai Medical School in 1997. Zhou’s research is directed at better understanding of the biology of epigenetic control of gene transcription of human genome to attain both the underlying basic principles and rational design of novel chemical compounds that modulate gene expression in chromatin. His research studies have broad implications in human biology and disease, ranging from cell development, to stem cell self-renewal and differentiation, and re-programming to human cancer and inflammation, as well as neurodegenerative disorders. Among his major contributions to science is the Zhou Lab's seminal discovery of the bromodomain as the acetyl-lysine binding domain ('chromatin reader') in gene transcription (Nature 1999), and their first demonstration of druggability and therapeutic potential of bromodomain proteins in